Literature DB >> 2081852

[Macular vitelliform degeneration in adults. Retrospective study of a series of 85 patients].

A Glacet-Bernard1, G Soubrane, G Coscas.   

Abstract

Since 1974 (Gass), many publications have referred to a macular abnormality that is similar to Best's vitelliform dystrophy, but occurs in adults and shows a normal or subnormal electro-oculogram. In our retrospective study, 85 patients with adult macular vitelliform degeneration were included; 31 patients out of 85 have been followed-up for periods ranging from one to ten years. Women (62,3%) were predominantly affected; the median age was 61 years (ranging from 37 to 81 years); family history did not reveal others affected members except in one case (mother and her son affected); electro-oculogram was recorded in 12 patients and was normal (8 patients) or slightly subnormal (4 patients). During follow-up, vitelliform lesions have shown progressive changes over many years, resulting in a round or oval atrophic area in the central retinal pigment epithelium. Visual acuity was fair at presentation but decreased progressively: at presentation, 43% of the eyes had visual acuity better or equal to 0.6; after 1 year, 59%; after 2 years, 28.5%; after 4 years, 20%, and only 8% of those followed-up for 10 years. Impairment of vision was usually related to alteration of the retinal pigment epithelium and macular atrophy, sometimes to subretinal neovascularization (14 eyes of 12 patients out of 157, or 15% of patients), or rarely to macular edema (2 cases). Several aspects of this disease are still controversial: firstly, the problem whether or not the disease represents a single nosological entity; secondarily its dominant inheritance. The analysis of our cases and of those already published seems to show that the macular changes observed are related to a single disease, well-defined by the epidemiology, the clinical aspects, the natural course. The late onset of the disease, the lack of constant familial involvement and the similarity with other retinal degenerative disorders seem to suggest that vitelliform macular lesions may represent a distinct subgroup of age-related macular degeneration, with a possible genetic predisposition.

Entities:  

Mesh:

Year:  1990        PMID: 2081852

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  7 in total

1.  En face enhanced depth imaging optical coherence tomography features in adult onset foveomacular vitelliform dystrophy.

Authors:  Nathalie Puche; Giuseppe Querques; Rocio Blanco-Garavito; Jennyfer Zerbib; Farah Gherdaoui; Julien Tilleul; Florence Coscas; Agnes Glacet-Bernard; Eric H Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-26       Impact factor: 3.117

2.  Multimodal imaging of adult-onset foveomacular vitelliform dystrophy.

Authors:  Seanna Grob; Yoshihiro Yonekawa; Dean Eliott
Journal:  Saudi J Ophthalmol       Date:  2014-04

3.  Adult-onset foveomacular vitelliform dystrophy and indocyanine green videoangiography.

Authors:  M Battaglia Parodi; D Iustulin; D Russo; G Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-03       Impact factor: 3.117

4.  Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy.

Authors:  Roberto Gallego-Pinazo; Rosa Dolz-Marco; Diamar Pardo-López; J Fernando Arevalo; Manuel Díaz-Llopis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-08       Impact factor: 3.117

5.  Electronegative electroretinogram associated with topiramate toxicity and vitelliform maculopathy.

Authors:  Irena Tsui; Daniel Casper; Chai Lin Chou; Stephen H Tsang
Journal:  Doc Ophthalmol       Date:  2007-10-03       Impact factor: 2.379

6.  [Clinical diagnostic prerequisites for adult vitelliform macular dystrophy].

Authors:  A B Renner; H Tillack; H Kraus; U Kellner; M H Foerster
Journal:  Ophthalmologe       Date:  2004-09       Impact factor: 1.059

7.  Natural course of adult-onset vitelliform lesions in eyes with and without comorbid subretinal drusenoid deposits.

Authors:  Craig Wilde; Mary Awad; Konstantinos Giannouladis; Arun Lakshmanan; Aaron Ming-Hon Yeung; Harminder Dua; Winfried M K Amoaku
Journal:  Int Ophthalmol       Date:  2020-03-04       Impact factor: 2.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.